Small-Cell Lung Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Small-Cell Lung Cancer - Pipeline Review, H1 2012, provides an overview of the Small-Cell Lung Cancer therapeutic pipeline. This report provides information on the therapeutic development for Small-Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer. Small-Cell Lung Cancer - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Small-Cell Lung Cancer.
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Small-Cell Lung Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Small-Cell Lung Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Small-Cell Lung Cancer 13
Small-Cell Lung Cancer Therapeutics under Development by Companies 15
Small-Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Small-Cell Lung Cancer Therapeutics – Products under Development by Companies 31
Small-Cell Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 35
Companies Involved in Small-Cell Lung Cancer Therapeutics Development 48
Bristol-Myers Squibb Company 48
Abbott Laboratories 49
Amgen Inc. 50
Eli Lilly and Company 51
GlaxoSmithKline plc 52
Dainippon Sumitomo Pharma Co., Ltd. 53
ZIOPHARM Oncology, Inc. 54
Millennium Pharmaceuticals, Inc. 55
Novartis AG 56
Cephalon, Inc. 57
ImmunoGen, Inc. 58
Nippon Kayaku Co., Ltd. 59
SuperGen, Inc. 60
Exelixis, Inc. 61
Menarini Group 62
Celgene Corporation 63
Bayer AG 64
Alchemia Limited 65
Hana Biosciences, Inc. 66
AEterna Zentaris Inc. 67
ImmunoCellular Therapeutics, Ltd. 68
Critical Outcome Technologies Inc. 69
Poniard Pharmaceuticals, Inc. 70
Threshold Pharmaceuticals, Inc. 71
Synta Pharmaceuticals Corp. 72
Simcere Pharmaceutical Group 73
MabVax Therapeutics, Inc. 74
Acceleron Pharma, Inc. 75
TRION Pharma GmbH 76
Celator Pharmaceuticals, Inc. 77
Ascenta Therapeutics, Inc. 78
Neotropix, Inc. 79
MolMed S.p.A. 80
Innogene Kalbiotech Pte Ltd. 81
Krankenhaus-GmbH 82
Polaris Group 83
Theradex Systems, Inc. 84
Small-Cell Lung Cancer – Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Combination Products 86
Assessment by Route of Administration 87
Assessment by Molecule Type 90
Drug Profiles 93
Sotatercept - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Amrubicin Hydrochloride - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Topotecan - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Etoposide + Cisplatin + Radiation Therapy - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Picoplatin - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Carboplatin + Etoposide + Thalidomide - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Camtobell + Cisplatin - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Etoposide + Cisplatin - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Carboplatin + Taxol - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Carboplatin + Etoposide + Pravastatin - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Cisplatin + Etoposide + Pravastatin - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Cyclophosphamide + Doxorubicin + Etoposide - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Cisplatin + Etoposide + Bevacizumab - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Ifosfamide + Carboplatin + Etoposide + Vincristine + Radiation Therapy - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 116
Irinotecan + Cisplatin + Radiation Therapy - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Topotecan + Cisplatin - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Etoposide + Carboplatin - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Epirubicin + Ifosfamide + Etoposide - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Cisplatin + Etoposide + Paclitaxel - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Etoposide + Cisplatin - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Cisplatin + Etoposide + Radiation Therapy - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Irinotecan + Cisplatin - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Cisplatin + Etoposide - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Cisplatin + Irinotecan - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Cisplatin + Etoposide - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Irinotecan + Cisplatin - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Irinotecan + Cisplatin + Etoposide - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Nogitecan - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Amrubicin + Cisplatin - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Cisplatin + Etoposide + Radiation Therapy - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 137
Cisplatin + Etoposide + Ifosfamide + Carboplatin + Radiation Therapy + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile 138
Product Description 138
Mechanism of Action 138
R&D Progress 139
Cisplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 141
cisplatin + cyclophosphamide + epirubicin hydrochloride + etoposide - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 143
Etoposide + Cisplatin - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Cisplatin + Etoposide + Topotecan - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
carboplatin + cisplatin + cyclophosphamide + doxorubicin hydrochloride + etoposide + ifosfamide + mesna + vincristine sulfate + radiation therapy - Drug Profile 146
Product Description 146
Mechanism of Action 147
R&D Progress 148
ifosfamide + carboplatin + etoposide - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
Cisplatin - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
Cisplatin + Etoposide + Topotecan - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Small-Cell Lung Cancer Therapeutics – Drug Profile Updates 154
Small-Cell Lung Cancer Therapeutics – Discontinued Products 156
Small-Cell Lung Cancer Therapeutics - Dormant Products 159
Small-Cell Lung Cancer – Product Development Milestones 171
Featured News & Press Releases 171
Dec 07, 2011: ZIOPHARM Receives European Patent Allowance For Palifosfamide 171
Nov 14, 2011: ZIOPHARM Oncology Announces Promising Data From Phase Ib Study Of Palifosfamide In Small Cell Lung And Other Cancers At AACR-NCI-EORTC Meeting 171
Oct 19, 2011: ROVI Announces Positive Results From Final Analysis Of Phase II Study Of Bemiparin 172
Oct 05, 2011: Sunshine Biopharma's Anticancer Compound Adva-27a Exhibits Strong Topoisomerase II Inhibition 172
Sep 28, 2011: Alchemia’s Cancer Treatment Shows Early Promise In Lung Cancer Trial 173
Sep 09, 2011: Alchemia Initiates Phase II Trial Of HA-Irinotecan In Small Cell Lung Cancer 174
Jul 06, 2011: Synta Announces Presentation Of Small Cell Lung Cancer Results At IASLC 14th World Conference On Lung Cancer 174
Jun 07, 2011: Cephalon Presents Encouraging Results Of Obatoclax In Extensive-Stage Small Cell Lung Cancer At ASCO Annual Meeting 175
Jun 03, 2011: MolMed Reports Top-line results From Phase II Trial Of NGR-hTNF + Doxorubicin In Small Cell Lung Cancer 176
May 18, 2011: Ludwig Institute For Cancer Research And Polaris Group Collaborates To Expand Development Of ADI-PEG 20 176
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 179
Contact Us 179
Disclaimer 17

List of Tables

Number of Products Under Development for Small-Cell Lung Cancer, H1 2012 13
Products under Development for Small-Cell Lung Cancer – Comparative Analysis, H1 2012 14
Number of Products under Development by Companies, H1 2012 16
Number of Products under Development by Companies, H1 2012 (Contd..1) 17
Number of Products under Development by Companies, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 26
Comparative Analysis by Late Stage Development, H1 2012 27
Comparative Analysis by Mid Clinical Stage Development, H1 2012 28
Comparative Analysis by Early Clinical Stage Development, H1 2012 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 30
Products under Development by Companies, H1 2012 31
Products under Development by Companies, H1 2012 (Contd..1) 32
Products under Development by Companies, H1 2012 (Contd..2) 33
Products under Development by Companies, H1 2012 (Contd..3) 34
Products under Investigation by Universities/Institutes, H1 2012 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 47
Bristol-Myers Squibb Company, H1 2012 48
Abbott Laboratories, H1 2012 49
Amgen Inc., H1 2012 50
Eli Lilly and Company, H1 2012 51
GlaxoSmithKline plc, H1 2012 52
Dainippon Sumitomo Pharma Co., Ltd., H1 2012 53
ZIOPHARM Oncology, Inc., H1 2012 54
Millennium Pharmaceuticals, Inc., H1 2012 55
Novartis AG, H1 2012 56
Cephalon, Inc., H1 2012 57
ImmunoGen, Inc., H1 2012 58
Nippon Kayaku Co., Ltd., H1 2012 59
SuperGen, Inc., H1 2012 60
Exelixis, Inc., H1 2012 61
Menarini Group, H1 2012 62
Celgene Corporation, H1 2012 63
Bayer AG, H1 2012 64
Alchemia Limited, H1 2012 65
Hana Biosciences, Inc., H1 2012 66
AEterna Zentaris Inc., H1 2012 67
ImmunoCellular Therapeutics, Ltd., H1 2012 68
Critical Outcome Technologies Inc., H1 2012 69
Poniard Pharmaceuticals, Inc., H1 2012 70
Threshold Pharmaceuticals, Inc., H1 2012 71
Synta Pharmaceuticals Corp., H1 2012 72
Simcere Pharmaceutical Group, H1 2012 73
MabVax Therapeutics, Inc., H1 2012 74
Acceleron Pharma, Inc., H1 2012 75
TRION Pharma GmbH, H1 2012 76
Celator Pharmaceuticals, Inc., H1 2012 77
Ascenta Therapeutics, Inc., H1 2012 78
Neotropix, Inc., H1 2012 79
MolMed S.p.A., H1 2012 80
Innogene Kalbiotech Pte Ltd., H1 2012 81
Krankenhaus-GmbH, H1 2012 82
Polaris Group, H1 2012 83
Theradex Systems, Inc., H1 2012 84
Assessment by Monotherapy Products, H1 2012 85
Assessment by Combination Products, H1 2012 86
Assessment by Stage and Route of Administration, H1 2012 89
Assessment by Molecule Type, H1 2012 92
Small-Cell Lung Cancer Therapeutics – Drug Profile Updates 154
Small-Cell Lung Cancer Therapeutics – Discontinued Products 156
Small-Cell Lung Cancer Therapeutics – Discontinued Products (Contd..1) 157
Small-Cell Lung Cancer Therapeutics – Discontinued Products (Contd..2) 158
Small-Cell Lung Cancer Therapeutics – Dormant Products 159
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..1) 160
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..2) 161
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..3) 162
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..4) 163
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..5) 164
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..6) 165
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..7) 166
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..8) 167
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..9) 168
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..10) 169
Small-Cell Lung Cancer Therapeutics – Dormant Products (Contd..11) 170

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H1 2012 13
Products under Development for Small-Cell Lung Cancer – Comparative Analysis, H1 2012 14
Products under Development by Companies, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 19
Late Stage Products, H1 2012 27
Mid Clinical Stage Products, H1 2012 28
Early Clinical Stage Products, H1 2012 29
Discovery and Pre-Clinical Stage Products, H1 2012 30
Assessment by Monotherapy Products, H1 2012 85
Assessment by Combination Products, H1 2012 86
Assessment by Route of Administration, H1 2012 87
Assessment by Stage and Route of Administration, H1 2012 88
Assessment by Molecule Type, H1 2012 90
Assessment by Stage and Molecule Type, H1 2012 91